Lenalidomide for mantle cell lymphoma.

Abstract

Mantle cell lymphoma accounts for 6% of all non-Hodgkin lymphomas. It is a biologically and clinically heterogeneous disease and treatment may be difficult, since most patients present at an older age, being unable to undergo intensive chemotherapy. Lenalidomide is an approved medication for relapsed mantle cell lymphoma in patients who received at least two lines of therapy, including bortezomib. New insights into the mechanisms of action of lenalidomide provided ground for novel combinations that may be more tolerable, while still efficient, for this patient population. In this review, we evaluate the current paradigm for lenalidomide in mantle cell lymphoma.

• Authors: Alan P Skarbnik, Andre H Goy
• Journal: Expert review of hematology (Expert Rev Hematol) Vol. 8 Issue 3 Pg. 257-64 (Jun 2015) ISSN: 1747-4094 [Electronic] England
• PMID: 25952533 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Angiogenesis Inhibitors
• Immunologic Factors
• Thalidomide
• Lenalidomide

Topics

• Angiogenesis Inhibitors (pharmacology, therapeutic use)
• Animals
• Humans
• Immunologic Factors (pharmacology, therapeutic use)
• Lenalidomide
• Lymphoma, Mantle-Cell (drug therapy)
• Neoplasm Recurrence, Local (drug therapy)
• Thalidomide (analogs & derivatives, pharmacology, therapeutic use)